



Author index

Volume 260 (1997)

- Alberti, M.M., see Dyer, R.G. 260, 1
Author, D., The effect of analytic uncertainty on clinical decision making 260, 97
- Barragán-González, E., J.A. López-Guerrero, P. Bolufer-Gilabert, M. Sanz-Alonso, J. De la Rubia-Comos, A. Sempere-Talens, The type of reverse transcriptase affects the sensitivity of some reverse transcription PCR methods 260, 73
- Bertuzzi, A., see Mingrone, G. 260, 27
- Biondi, R., see Capodicasa, E. 260, 35
- Blaabjerg, O., see Hyltoft Petersen, P. 260, 189
- Bolufer-Gilabert, P., see Barragán-González, E. 260, 73
- Büttner, J., Diagnostic validity as a theoretical concept and as a measurable quantity 260, 131
- Capodicasa, E., C. Tassi, R. Rossi, L. Mezzasoma, M. Valiani, R. Biondi, Effect of antithorstatic hypokinetic/hypodynamia on urinary endothelin-1 and N-acetyl- β -D-glucosaminidase excretion in rats 260, 35
- Chiang, A.N., B. Hwang, G.C. Shaw, B.C. Lee, J.H. Lu, C.C.L. Meng, P. Chou, Changes in plasma levels of lipids and lipoprotein composition in patients with Kawasaki disease 260, 15
- Chou, P., see Chiang, A.N. 260, 15
- Davie, S.J., see Gould, B.J. 260, 49
- De la Rubia-Comos, J., see Barragán-González, E. 260, 73
- De Smet, R., see Mingrone, G. 260, 27
- de Verdier, C.-H., see Hyltoft Petersen, P. 260, 189
- Doumas, B.T., The evolution and limitations of accuracy and precision standards 260, 145
- Dyer, R.G., M.W. Stewart, J. Mitcheson, K. George, M.M. Alberti, M.F. Laker, 7-Ketosterol, a specific indicator of lipoprotein oxidation, and malondialdehyde in non-insulin dependent diabetes and peripheral vascular disease 260, 1
- Fraser, C.G., see Hyltoft Petersen, P. 260, 189
- Gandolfi, A., see Mingrone, G. 260, 27
- George, K., see Dyer, R.G. 260, 1
- Gould, B.J., S.J. Davie, J.S. Yudkin, Investigation of the mechanism underlying the variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia 260, 49
- Greco, A.V., see Mingrone, G. 260, 27
- Groth, T., see Hyltoft Petersen, P. 260, 189
- Handorf, C.R., Assuring quality in laboratory testing at the point of care 260, 207
- Howanitz, P.J., G.A. Tetrault, S.J. Steindel, Clinical laboratory quality control: a costly process now out of control 260, 163
- Hørder, M., see Hyltoft Petersen, P. 260, 189
- Hwang, B., see Chiang, A.N. 260, 15
- Hyltoft Petersen, P., C.-H. de Verdier, T. Groth, C.G. Fraser, O. Blaabjerg, M. Hørder, The influence of analytical bias on diagnostic misclassifications 260, 189
- Klee, G., A conceptual model for establishing tolerance limits for analytic bias and imprecision based on variations in population test distributions 260, 175

- Laker, M.F., see Dyer, R.G. 260, 1
Lascelles, C.V., P.A. Quant, Investigation of human hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme A synthase in post-mortem or biopsy tissue 260, 85
Lee, B.C., see Chiang, A.N. 260, 15
López-Guerrero, J.A., see Barragán-González, E. 260, 73
Lu, J.H., see Chiang, A.N. 260, 15

Meng, C.C.L., see Chiang, A.N. 260, 15
Mezzasoma, L., see Capodicasa, E. 260, 35
Mingrone, G., R. De Smet, A.V. Greco, A. Bertuzzi, A. Gandolfi, S. Ringoir, R. Vanholder, Serum uremic toxins from patients with chronic renal failure displace the binding of L-tryptophan to human serum albumin 260, 27
Mitcheson, J., see Dyer, R.G. 260, 1

Quant, P.A., see Lascelles, C.V. 260, 85

Ringoir, S., see Mingrone, G. 260, 27
Rojas, G., see Sorell Gómez, L. 260, 65
Rossi, R., see Capodicasa, E. 260, 35

Sanz-Alonso, M., see Barragán-González, E. 260, 73
Sempere-Talens, A., see Barragán-González, E. 260, 73
Shaw, G.C., see Chiang, A.N. 260, 15
Sorell Gómez, L., G. Rojas, A simple visual immunoassay (VIA) for rapid identification of high lipoprotein(a) blood levels 260, 65
Steindel, S.J., see Howanitz, P.J. 260, 163
Stewart, M.W., see Dyer, R.G. 260, 1

Tassi, C., see Capodicasa, E. 260, 35
Tetrault, G.A., see Howanitz, P.J. 260, 163

Valiani, M., see Capodicasa, E. 260, 35
Vanholder, R., see Mingrone, G. 260, 27

Werner, M., Linking analytic performance goals to medical outcome 260, 99
Witte, D.L., The complex connections between test properties and relevant outcomes: widening the perspective 260, 117
Yudkin, J.S., see Gould, B.J. 260, 49



Subject index

Volume 260 (1997)

Albumin binding; Uremic toxins; Chronic renal failure; L-Tryptophan **260**, 27

Aminoglycosides; Predictive value; Cognition; Hemochromatosis; Error rates; Analytical goals **260**, 117

Analytical goals; Analytical quality specifications; Glycated haemoglobin; S-Cholesterol; S-Transferrin **260**, 189

Analytical goals; Predictive value; Cognition; Hemochromatosis; Aminoglycosides; Error rates **260**, 117

Analytical quality specifications; Analytical goals; Glycated haemoglobin; S-Cholesterol; S-Transferrin **260**, 189

Analytic bias; Analytic goals; Imprecisions; Clinical decision theory; Quality control; Tolerance limits **260**, 175

Analytic goals; Analytic bias; Imprecisions; Clinical decision theory; Quality control; Tolerance limits **260**, 175

Analytic performance; Medical goals; Tolerance limits; Clinical decisions; Medical reasoning **260**, 99

Antiorthostasis; Endothelin-1 (ET-1); N-acetyl- β -D-glucosaminidase (NAG); Kidney; Urine; Rat **260**, 35

Apolipoproteins; Lipids; Lipoproteins; Kawasaki disease **260**, 15

Atherosclerosis; Diabetes; Malondialdehyde; Lipoproteins; 7-Ketocholesterol **260**, 1

Avian Myelomatosis Virus (AMV); Reverse transcription (RT); Murine Moloney Leukaemia Virus (MMLV); RT-PCR; PML/RAR α ; CBF β /MYH11; Cytokeratin K19 **260**, 73

CBF β /MYH11; Reverse transcription (RT); Avian Myelomatosis Virus (AMV); Murine Moloney Leukaemia Virus (MMLV); RT-PCR; PML/RAR α ; Cytokeratin K19 **260**, 73

Chronic renal failure; Uremic toxins; L-Tryptophan; Albumin binding **260**, 27

Clinical assay; Human hepatic mHMG-CoA synthase; Succinylation; Ketogenesis; Liver needle biopsy; Postmortem tissue **260**, 85

Clinical decisions; Analytic performance; Medical goals; Tolerance limits; Medical reasoning **260**, 99

Clinical decision theory; Analytic goals; Analytic bias; Imprecisions; Quality control; Tolerance limits **260**, 175

Cognition; Predictive value; Hemochromatosis; Aminoglycosides; Error rates; Analytical goals **260**, 117

Cytokeratin K19; Reverse transcription (RT); Avian Myelomatosis Virus (AMV); Murine Moloney Leukaemia Virus (MMLV); RT-PCR; PML/RAR α ; CBF β /MYH11 **260**, 73

- Diabetes;** Atherosclerosis; Malondialdehyde; Lipoproteins; 7-Ketocholesterol **260**, 1
- Diagnostic validity;** Laboratory test; Laboratory finding; Efficiency **260**, 131
- 2,3-Diphosphoglycerate;** Glycated haemoglobin; Glycated albumin; Fructosamine; Glucose tolerance test; Glucose permeability of erythrocytes **260**, 49
- Efficiency;** Laboratory test; Laboratory finding; Diagnostic validity **260**, 131
- Endothelin-1 (ET-1);** Antiorthostasis; *N*-acetyl- β -D-glucosaminidase (NAG); Kidney; Urine; Rat **260**, 35
- Error rates;** Predictive value; Cognition; Hemochromatosis; Aminoglycosides; Analytical goals **260**, 117
- Fructosamine;** Glycated haemoglobin; Glycated albumin; Glucose tolerance test; Glucose permeability of erythrocytes; 2,3-Diphosphoglycerate **260**, 49
- Glucose permeability of erythrocytes;** Glycated haemoglobin; Glycated albumin; Fructosamine; Glucose tolerance test; 2,3-Diphosphoglycerate **260**, 49
- Glucose tolerance test;** Glycated haemoglobin; Glycated albumin; Fructosamine; Glucose permeability of erythrocytes; 2,3-Diphosphoglycerate **260**, 49
- Glycated albumin;** Glycated haemoglobin; Fructosamine; Glucose tolerance test; Glucose permeability of erythrocytes; 2,3-Diphosphoglycerate **260**, 49
- Glycated haemoglobin;** Analytical goals; Analytical quality specifications; S-Cholesterol; S-Transferrin **260**, 189
- Glycated haemoglobin;** Glycated albumin; Fructosamine; Glucose tolerance test; Glucose permeability of erythrocytes; 2,3-Diphosphoglycerate **260**, 49
- Hemochromatosis;** Predictive value; Cognition; Aminoglycosides; Error rates; Analytical goals **260**, 117
- Human hepatic mHMG-CoA synthase;** Succinylation; Ketogenesis; Clinical assay; Liver needle biopsy; Postmortem tissue **260**, 85
- Imprecisions;** Analytic goals; Analytic bias; Clinical decision theory; Quality control; Tolerance limits **260**, 175
- Kawasaki disease;** Lipids; Lipoproteins; Apolipoproteins **260**, 15
- 7-Ketocholesterol;** Atherosclerosis; Diabetes; Malondialdehyde; Lipoproteins **260**, 1
- Ketogenesis;** Human hepatic mHMG-CoA synthase; Succinylation; Clinical assay; Liver needle biopsy; Postmortem tissue **260**, 85
- Kidney;** Antiorthostasis; Endothelin-1 (ET-1); *N*-acetyl- β -D-glucosaminidase (NAG); Urine; Rat **260**, 35
- Laboratory costs;** Quality control; Timeliness; Quality costs; Quality improvement; Laboratory management **260**, 163
- Laboratory finding;** Laboratory test; Diagnostic validity; Efficiency **260**, 131
- Laboratory management;** Quality control; Laboratory costs; Timeliness; Quality costs; Quality improvement **260**, 163
- Laboratory testing;** Point of care; Quality **260**, 207
- Laboratory test;** Laboratory finding; Diagnostic validity; Efficiency **260**, 131
- Lipids;** Lipoproteins; Apolipoproteins; Kawasaki disease **260**, 15
- Lipoprotein(a);** Visual immunoassay; Monoclonal antibodies **260**, 65
- Lipoproteins;** Atherosclerosis; Diabetes; Malondialdehyde; 7-Ketocholesterol **260**, 1
- Lipoproteins;** Lipids; Apolipoproteins; Kawasaki disease **260**, 15
- Liver needle biopsy;** Human hepatic mHMG-CoA synthase; Succinylation; Ketogenesis; Clinical assay; Postmortem tissue **260**, 85

- L-Tryptophan;** Uremic toxins; Chronic renal failure; Albumin binding **260**, 27
- Malondialdehyde;** Atherosclerosis; Diabetes; Lipoproteins; 7-Ketcholesterol **260**, 1
- Medical goals;** Analytic performance; Tolerance limits; Clinical decisions; Medical reasoning **260**, 99
- Medical reasoning;** Analytic performance; Medical goals; Tolerance limits; Clinical decisions **260**, 99
- Monoclonal antibodies;** Lipoprotein(a); Visual immunoassay **260**, 65
- Murine Moloney Leukaemia Virus (MMLV);** Reverse transcription (RT); Avian Myelomatosis Virus (AMV); Murine Moloney Leukaemia Virus (MMLV); RT-PCR; PML/RAR α ; CBF β /MYH11; Cytokeratin K19 **260**, 73
- N-acetyl- β -D-glucosaminidase (NAG);** Antiothostasis; Endothelin-1 (ET-1); Kidney; Urine; Rat **260**, 35
- PML/RAR α ;** Reverse transcription (RT); Avian Myelomatosis Virus (AMV); Murine Moloney Leukaemia Virus (MMLV); RT-PCR; CBF β /MYH11; Cytokeratin K19 **260**, 73
- Point of care;** Laboratory testing; Quality **260**, 207
- Postmortem tissue;** Human hepatic mHMG-CoA synthase; Succinylation; Ketogenesis; Clinical assay; Liver needle biopsy **260**, 85
- Predictive value;** Cognition; Hemochromatosis; Aminoglycosides; Error rates; Analytical goals **260**, 117
- Quality control;** Analytic goals; Analytic bias; Imprecisions; Clinical decision theory; Tolerance limits **260**, 175
- Quality control;** Laboratory costs; Timeliness; Quality costs; Quality improvement; Laboratory management **260**, 163
- Quality costs;** Quality control; Laboratory costs; Timeliness; Quality improvement; Laboratory management **260**, 163
- Quality improvement;** Quality control; Laboratory costs; Timeliness; Quality costs; Laboratory management **260**, 163
- Quality;** Laboratory testing; Point of care **260**, 207
- Rat;** Antiothostasis; Endothelin-1 (ET-1); N-acetyl- β -D-glucosaminidase (NAG); Kidney; Urine **260**, 35
- Reverse transcription (RT);** Avian Myelomatosis Virus (AMV); Murine Moloney Leukaemia Virus (MMLV); RT-PCR; PML/RAR α ; CBF β /MYH11; Cytokeratin K19 **260**, 73
- RT-PCR;** Reverse transcription (RT); Avian Myelomatosis Virus (AMV); Murine Moloney Leukaemia Virus (MMLV); PML/RAR α ; CBF β /MYH11; Cytokeratin K19 **260**, 73
- S-Cholesterol;** Analytical goals; Analytical quality specifications; Glycated haemoglobin; S-Transferrin **260**, 189
- S-Transferrin;** Analytical goals; Analytical quality specifications; Glycated haemoglobin; S-Cholesterol **260**, 189
- Succinylation;** Human hepatic mHMG-CoA synthase; Ketogenesis; Clinical assay; Liver needle biopsy; Postmortem tissue **260**, 85
- Timeliness;** Quality control; Laboratory costs; Quality costs; Quality improvement; Laboratory management **260**, 163
- Tolerance limits;** Analytic goals; Analytic bias; Imprecisions; Clinical decision theory; Quality control **260**, 175
- Tolerance limits;** Analytic performance; Medical goals; Clinical decisions; Medical reasoning **260**, 99
- Uremic toxins;** Chronic renal failure; L-Tryptophan; Albumin binding **260**, 27
- Urine;** Antiothostasis; Endothelin-1 (ET-1); N-acetyl- β -D-glucosaminidase (NAG); Kidney; Rat **260**, 35
- Visual immunoassay;** Lipoprotein(a); Monoclonal antibodies **260**, 65